The news that the world’s first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer “highlights a truly significant advance in the management of breast cancer,” says Edith Perez, M.D., director of Mayo Clinic’s Breast Clinic in Jacksonville, Fla.
The Nuffield Council on Bioethics has set out guidelines on when to give intensive care to extremely premature babies. Advice for parents and doctors is provided, on a week-by-week basis, for treating babies born before 22 weeks up to those born after 25 weeks.
A new optical imaging technique, developed at the Wellman Center for Photomedicine at Massachusetts General Hospital, can provide three-dimensional microscopic views of the inner surfaces of blood vessels and gastrointestinal organs.
Pledging his eyes, Health Minister Anbumani Ramadoss today said that the country India hoped to achieve its target of vision to all by the year 2015.
The University of Maryland School of Medicine has created a Program in Minority Health and Health Disparities Education and Research (PMHHD). The goal of the program is to educate current and future health professionals about issues related to health disparities, to support relevant multidisciplinary research and to foster quality clinical care for minorities and diverse populations.
To mark the end of Mouth Cancer Awareness Week which started on Sunday 12th November the Mouth Cancer Foundation is holding a giant sponsored walk which will take place in London. Hundreds of walkers from across the country are already signed up to take part in the free 10k sponsored Mouth Cancer Walking event designed to raise awareness of Mouth Cancer.
Passive smoking does cause respiratory troubles in healthy adults, a new study confirms. The study is in the November issue of the American Journal of Respiratory and Critical Care Medicine.
A combined analysis of two landmark clinical glaucoma trials — the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS) — confirms the benefit of a five-year risk assessment model to help ophthalmologists better predict which patients have an increased risk of developing glaucoma. Glaucoma is the second leading cause of blindness in the world, affecting approximately 70 million people, and can lead to blindness if left untreated. These new data were presented this week at the annual American Academy of Ophthalmology meeting.
An observational study of more than 64,000 asthma patients demonstrated that patients receiving treatment with Advair Diskus (fluticasone propionate and salmeterol inhalation powder) had a significant risk reduction in emergency department visits due to asthma versus patients treated with fluticasone propionate (FP) alone.
A survey of more than 1,300 asthma patients found that the majority of respondents (61 percent) had uncontrolled asthma based on their Asthma Control Test (ACT) score, and nearly one-third (29 percent) of those were not aware that their asthma was uncontrolled. Uncontrolled asthma may place patients at risk for increased symptoms, sudden attacks, hospitalization and even death from asthma.